Compare PRCH & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PRCH | ENGN |
|---|---|---|
| Founded | 2012 | 1999 |
| Country | United States | Canada |
| Employees | N/A | 82 |
| Industry | Computer Software: Prepackaged Software | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 753.7M | 647.1M |
| IPO Year | 2019 | N/A |
| Metric | PRCH | ENGN |
|---|---|---|
| Price | $6.97 | $7.68 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 6 |
| Target Price | $18.00 | ★ $21.08 |
| AVG Volume (30 Days) | ★ 1.1M | 239.1K |
| Earning Date | 05-05-2026 | 03-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 90.91 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $482,414,000.00 | N/A |
| Revenue This Year | $3.89 | N/A |
| Revenue Next Year | $16.80 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 10.18 | N/A |
| 52 Week Low | $4.65 | $2.66 |
| 52 Week High | $19.44 | $12.25 |
| Indicator | PRCH | ENGN |
|---|---|---|
| Relative Strength Index (RSI) | 43.97 | 53.24 |
| Support Level | $6.54 | $6.04 |
| Resistance Level | $8.29 | $8.14 |
| Average True Range (ATR) | 0.42 | 0.51 |
| MACD | -0.01 | 0.18 |
| Stochastic Oscillator | 31.52 | 97.02 |
Porch Group Inc is a vertical software company reinventing the home services and insurance industries. It has four reportable segments: Insurance Services, Software & Data, Consumer Services, and Corporate. The majority of revenue is from the Insurance segment. The Insurance Services segment manages and operates the Reciprocal, providing services related, but not limited, to underwriting, policy renewal, risk management, insurance portfolio management, financial management, and setting investment guidelines in exchange for commissions and fees.
enGene Holdings Inc is a clinical-stage biotechnology company mainstreaming genetic medicine through the delivery of therapeutics to mucosal tissues and other organs, with the goal of creating new ways to address diseases with high clinical needs, beginning with non-muscle invasive bladder cancer (NMIBC). The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.